# Natera, Inc. (NTRA) Investor Outlook: Exploring a 39.99% Upside with Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/natera-inc-ntra-investor-outlook-exploring-a-39-99-upside-with-strong-buy-ratings/4121251799
- Published: 2026-05-18T10:10:49+01:00
- Author: Madison Wilson

Natera, Inc. (NASDAQ: NTRA) is making waves in the healthcare sector, standing out
as a key player in the diagnostics and research industry. With a market capitalization
of $26.69 billion, this Austin-based company is at the forefront of molecular testing
services, offering a suite of innovative products that cater to various medical 
needs, from cancer monitoring to prenatal testing.

Currently trading at $186.36, Natera’s stock has experienced a slight dip of 0.05%,
but the company’s long-term growth prospects remain robust. Investors may find the
potential upside particularly appealing, with analysts setting a target price range
between $193.00 and $300.00, averaging at $260.89. This suggests a substantial potential
upside of nearly 40%, a figure that individual investors should not overlook.

One of the most compelling aspects of Natera’s market performance is its strong 
revenue growth, recorded at an impressive 38.80%. This growth trajectory underscores
the effectiveness of its product offerings, which include the Signatera ctDNA blood
test for cancer monitoring and the Panorama non-invasive prenatal test, among others.
However, it’s important to note that the company is currently operating at a loss,
with an EPS of -1.62 and a return on equity of -15.02%. Despite these figures, the
company has managed to generate a free cash flow of over $136 million, providing
a cushion for further investment in research and development.

Natera’s valuation metrics present a mixed picture. The trailing P/E ratio is unavailable,
and the forward P/E is a steep -484.97, indicating that the company is investing
heavily in its future growth at the expense of short-term profitability. This is
a common scenario in high-growth sectors, where companies prioritize expansion and
innovation over immediate earnings.

From a technical analysis perspective, Natera’s stock is positioned just below its
50-day and 200-day moving averages, indicating potential volatility. The Relative
Strength Index (RSI) stands at 66.67, suggesting that the stock is nearing overbought
territory, a factor that might prompt short-term corrections. The MACD value of -
2.08, coupled with a signal line of -0.12, reflects a bearish trend, which investors
should monitor closely.

The company’s commitment to innovation is further evidenced by its strategic partnerships,
such as the collaboration with BGI Genomics Co., Ltd., aimed at advancing genetic
testing assays. These alliances are pivotal in enhancing Natera’s market reach and
operational capabilities.

Analyst sentiment towards Natera is overwhelmingly positive, with 17 buy ratings
and only two hold recommendations. Notably, there are no sell ratings, reinforcing
the optimistic outlook for the stock. The absence of a dividend yield aligns with
the company’s growth-focused strategy, as it reinvests earnings into expanding its
cutting-edge testing services.

For investors, Natera represents a compelling opportunity to capitalize on the burgeoning
field of molecular diagnostics. While the stock carries inherent risks associated
with its current financial performance and market volatility, the potential for 
significant upside makes it an attractive consideration for those looking to invest
in the future of healthcare technology. As the company continues to innovate and
expand its offerings, Natera remains a stock worth watching closely.

Share on: